Biotech Veteran Bob Langer Teams Up with Son in New Venture Firm T.Rx Capital.
ByAinvest
Thursday, Sep 18, 2025 6:10 am ET1min read
MRNA--
T.Rx Capital held its final closing in July, falling short of its initial $125 million target. Despite this, the firm has secured significant backing, including a substantial investment from a large wealth-management firm [2]. The fund is poised to support innovative startups in the life sciences and healthcare technology sectors, with a focus on cutting-edge technologies such as antibody therapeutics, cell therapies, gene therapies, and diagnostics.
The venture firm's formation comes at a time when the biotechnology and healthcare sectors are experiencing rapid growth and innovation. With Langer's extensive experience and network, T.Rx Capital aims to identify and nurture promising startups that have the potential to revolutionize these industries.
Bob Langer, co-founder of Moderna, has teamed up with his son Michael and other healthcare-industry veterans to form T.Rx Capital, a new venture firm that has raised $77.5 million to invest in life sciences and healthcare-technology startups. T.Rx secured an anchor investor and held a final closing on the fund in July, short of its $125 million target.
Bob Langer, the co-founder of Moderna and a pioneer in biotechnology, has joined forces with his son Michael and other healthcare-industry veterans to establish T.Rx Capital, a new venture firm focused on life sciences and healthcare-technology startups. The fund, based in Boston, has successfully raised $77.5 million to date, with an anchor investor contributing to the effort [2].T.Rx Capital held its final closing in July, falling short of its initial $125 million target. Despite this, the firm has secured significant backing, including a substantial investment from a large wealth-management firm [2]. The fund is poised to support innovative startups in the life sciences and healthcare technology sectors, with a focus on cutting-edge technologies such as antibody therapeutics, cell therapies, gene therapies, and diagnostics.
The venture firm's formation comes at a time when the biotechnology and healthcare sectors are experiencing rapid growth and innovation. With Langer's extensive experience and network, T.Rx Capital aims to identify and nurture promising startups that have the potential to revolutionize these industries.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet